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Gemcitabine Combined with Capecitabine Compared to Gemcitabine
with or without Erlotinib as First-Line Chemotherapy in
Patients with Advanced Pancreatic Cancer
Purpose
The purpose of this study is to retrospectively compare the efficacy and tolerability between
three regimens for first-line chemotherapy—gemcitabine plus capecitabine (GEM-X),
gemcitabine plus erlotinib (GEM-T), and gemcitabine monotherapy (GEM)—in patients with
advanced pancreatic cancer.
Materials and Methods
There was a total of 127 patients who underwent chemotherapy for pancreatic cancer
between January 2007 and November 2011 at our institution. Patients were treated with
either GEM (gemcitabine 1,000 mg/m2 on days 1, 8, and 15 every 4 weeks), GEM-T
(gemcitabine 1,000 mg/m2 on days 1 and 8 every 3 weeks and erlotinib 100 mg daily), or
GEM-X (gemcitabine 1,000 mg/m2 on days 1 and 8 every 3 weeks and capecitabine 850
mg/m2 twice daily for 2 weeks followed by 1 week’s rest) as the first-line treatment.
Progression-free survival (PFS), overall survival (OS), objective response rate (ORR), and tox-
icity were evaluated.
Results
The patient population was divided into groups depending on their first-line treatment: GEM
(n=47), GEM-T (n=44), and GEM-X (n=36). GEM-X significantly improved ORR (21.2% vs.
12.7% and 15.9%), PFS (8.9 vs. 5.2 and 3.9 months; p < 0.001), and OS (12.1 vs. 10.4
and 9.9 months; p = 0.03) compared to GEM and GEM-T, respectively. There were higher
incidences of some non-hematologic adverse events with GEM-X and GEM-T compared to
GEM, but most were grade 1 or 2. 
Conclusion
GEM-X presented better clinical efficacy and acceptable tolerability than GEM-T and GEM
in advanced pancreatic cancers. It is worthy to further investigate which agent has a clinical
advantage as a combination drug with gemcitabine in pancreatic cancer and to explore the
predictive markers leading to personalize anti-cancer treatment.
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Introduction
Pancreatic cancer is one of the most desperate cancers,
causing approximately 266,000 deaths worldwide in 2008 [1].
The majority of these cases are diagnosed at unresectable
stages, and the prognosis is extremely poor, despite curative
resection. Currently, the median overall survival of patients
with locally advanced and metastatic pancreatic cancers is
only 6 to 12 months if treated with standard chemotherapy
[2-5].
Fifteen years ago, gemcitabine was used as a first-line
chemotherapy to extend the overall survival (OS) to 5.65
months from 4.41 months in advanced pancreas cancer
patients who received fluorouracil [2]. Therefore, gemc-
itabine became the standard treatment for patients in
advanced stages. Since then, randomized phase III trials of
cytotoxic or biologic drugs (erlotinib [3], capecitabine [4,5],
fluorouracil [6], oxaliplatin [7], cisplatin [8]), combined with
gemcitabine, have exhibited potential efficacy compared
with gemcitabine alone [9].
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Of the phase III clinical trials, erlotinib (Tarceva; Roche)
have presented promising results as a gemcitabine combina-
tion partner in pancreatic cancer. Erlotinib combined with
gemcitabine demonstrated an improvement in survival
compared to gemcitabine monotherapy (GEM; median, 6.24
months vs. 5.91 months; p=0.038) without improving the
objective response rate (ORR) [3]. Currently, GEM and
gemcitabine plus erlotinib (GEM-T) combination have been
accepted as first-line chemotherapies for metastatic pancre-
atic cancer based on high-level evidence [9,10]. Though
capecitabine combined with gemcitabine improved ORR
(19.1% vs. 12.4%, p=0.034) and progression-free survival
(PFS) (hazard ratio [HR], 0.78; p=0.004) of pancreatic cancer
patients, survival benefit of the regimen was not significant
(HR, 0.86; p=0.08) compared with gemcitabine alone [4].
However, several meta-analysis reported that gemcitabine
combined with capecitabine presented a significant increase
in survival compared to gemcitabine alone [11,12].
The issue of which agent may be the best combination with
gemcitabine for pancreas cancer has not been studied thus
far. The aim of this study is to retrospectively compare the
efficacy and toxicity of capecitabine or erlotinib in combina-
tion with gemcitabine compared with gemcitabine alone in
patients with locally advanced or metastatic pancreatic
cancer, and to determine which regimen exhibits a more 




We collected the data of patients who were diagnosed as
inoperable pancreatic adenocarcinoma between January 2007
and November 2011 at the Gangnam Severance Cancer
Hospital in South Korea. Patients enrollment eligibility was
as follows: histologically or cytologically confirmed ductal
adenocarcinoma of the pancreas; unresectable/metastatic
disease; treated with one of GEM, gemcitabine plus
capecitabine (GEM-X), and GEM-T as first-line treatment;
measurable or evaluable lesion; age more than 18 years;
Eastern Cooperative Oncology Group (ECOG) performance
status (PS) 0, 1, or 2; and adequate hematologic (granulocyte
count, ! 1,500"106/L; platelet count, !100"109/L), hepatic
(bilirubin < 1.5" upper limit of normal [ULN]), and renal
function (serum creatinine < 1.5" ULN) before first-line
chemotherapy. Prior radiotherapy for local disease was
allowed if the disease progression had been documented and
if radiotherapy was completed at least 4 weeks before
enrollment. Prior chemotherapy was not permitted, except
for postoperative adjuvant treatment or radiosensitizers. 
2. Treatment
Chemotherapy regimen for each patient was determined
by the physician in charge. For the GEM group, gemcitabine
(1,000 mg/m2) was given by a 30-minute intravenous
infusion on days 1, 8 and 15, every 4 weeks. For GEM-X and
GEM-T groups, gemcitabine (1,000 mg/m2) was adminis-
tered on days 1 and 8, in 3-week cycles. Erlotinib was taken
orally at 100 mg daily. Capecitabine was administered orally
at 1,700 mg/m2/day (850 mg/m2 twice daily) for 2 weeks,
followed by a 1-week rest. All treatments were administered
until disease progression or intolerable toxicity. The
chemotherapy doses could be reduced or delayed (no more
than 1 cycle) to allow recovery from toxicity. Dose reduction
in gemcitabine and capecitabine was in accordance to two
levels, 850 mg/m2 (level 1) and 700 mg/m2 (level 2) for
gemcitabine and 1,500 mg/m2 (level 1) and 1,200 mg/m2
(level 2) for capecitabine. Patients with poorly tolerated
diarrhea, skin adverse drug reaction, or any other adverse
events related with erlotinib, were managed with drug inter-
ruption, followed by a restart of erlotinib. This study was
approved by the Institutional Review Board of the Yonsei
University. 
3. Assessment
The pretreatment baseline evaluation included a complete
medical history, a physical examination, vital signs, electro-
cardiogram, chest radiography, and routine laboratory tests.
The serum carbohydrate antigen (CA) 19-9 level was
assessed at the baseline. Tumor assessment was performed
by a spiral computed tomography scan at the baseline, every
2 cycles. The radiologic tumor response was evaluated in
accordance to the Response Evaluation Criteria in Solid
Tumors (RECIST). Toxicity was assessed according to the
National Cancer Institute Common Toxicity Criteria ver. 3.0.
Clinical and laboratory assessments were conducted
throughout the study.
4. Statistical analysis
The primary end point was PFS, and the secondary end
points were OS and ORR. PFS was calculated from the date
of initial drug administration to the date of either disease
progression or death, or it was censored at the last follow up.
OS was calculated from the date of initial drug administra-
Jae Yun Lim, Chemotherapy for Pancreatic Cancer
268 CANCER  RESEARCH  AND  TREATMENT
tion to the date of death from any cause, or it was censored
at the last follow up. Both PFS and OS estimates were calcu-
lated using the Kaplan-Meier method, and the survival
curves were compared among the treatment arms using the
log-rank test. The HR with 95% confidence interval (CI) was
used as the primary estimate of the difference between the
two arms. The effects of potential prognostic factors were
assessed using the Cox’s proportional hazards model. The
proportions were compared across the groups using the !2
test or Fisher’s exact test. Statistical analyses were done with
PASW statistics ver. 18.0 (SPSS Inc., Chicago, IL). A p < 0.05
was considered to be statistically significant.
Results
1. Patient characteristics
A total of 127 patients were enrolled in this study. Patients
received one of the following treatments: GEM (n=47),
GEM-T (n=44), or GEM-X (n=36). The median follow-up
duration was 27.8 months (range, 1.5 to 71.9 months). Their
baseline characteristics are described in Table 1. Patients in
the GEM arm were statistically older than the others.
Prognostic factors, such as ECOG PS, disease extent, and
baseline CA 19-9 level, were not different between the three
groups, except disease extent between the GEM and GEM-T
arms. The proportion of locally advanced disease, which
presents a better prognosis than distant and recurred
Table 1. Patient characteristics
Characteristic Total (n=127) GEM (n=47) GEM-T (n=44) GEM-X (n=36)
Age (yr)
Median (range) 65 (32-84) 68 (41-84) 63 (32-78) 63 (38-77)
Gender
Male 72 (56.7) 25 (53.2) 25 (56.8) 22 (61.1)
ECOG performance status
0 or 1 116 (91.3) 41 (87.2) 41 (93.2) 34 (94.5)
2 11 (8.7) 6 (12.8) 3 (6.8) 2 (5.5)
Extent of disease 
Locally advanced 46 (36.2) 21 (44.7) 11 (25) 14 (38.9)
Distant metastatic 68 (53.5) 25 (53.2) 26 (59.1) 17 (47.2)
Recurred 13 (10.3) 1 (2.1) 7 (15.9) 5 (13.9)
CA 19-9 > 500 U/mL 64 (51.2) 25 (54.3) 23 (53.5) 16 (44.4)
Primary site
Head 73 (57.5) 30 (63.8) 22 (50) 21 (58.3)
Body 36 (28.3) 12 (25.5) 14 (31.8) 10 (27.8)
Tail 14 (11) 4 (8.5) 6 (13.6) 4 (11)
Total 2 (1.5) 1 (2.1) 0 ( 1 (2.8)
Metastatic site
Piver 49 (38.6) 13 (27.7) 21 (47.7) 15 (41.7)
Peritoneum 22 (17.3) 9 (19.1) 7 (15.9) 6 (16.7)
Lung 16 (12.6) 11 (23.4) 4 (9) 1 (2.8)
Distant lymph node 8 (6.3) 3 (6.4) 2 (4.5) 3 (8.3)
Other 7 (5.5) 2 (4.2) 4 (9) 1 (2.8)
Prior therapy
Chemotherapya) 11 (8.7) 0 (0) 6 (13.6) 5 (13.9)
Radiotherapy 7 (5.5) 1 (2.1) 4 (9) 2 (5.5)
Values are presented as number (%). GEM, gemcitabine; GEM-T, gemcitabine plus erlotinib; GEM-X, gemcitabine plus
capecitabine; ECOG, Eastern Cooperative Oncology Group; CA 19-9, carbohydrate antigen 19-9 (normal range, 0.8 to 24.0).
a)Used as a radiosensitizer or adjuvant treatment.
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diseases, was higher in the GEM arm than in the GEM-T arm
(44.7 vs. 25%, p=0.049). Locally advanced disease was
present in 36.2% of all cases. The pancreatic head was the
most common location of the primary lesions (57.5%). The
CA 19-9 level was over the upper normal limit in 107 patients
(84.3%). Patients were grouped into high or low CA 19-9
group by the median level of 500 U/mL. Prior chemotherapy
and radiotherapy were administered as adjuvant treatments
after curative resection of pancreatic cancer.
After the protocol-specified treatment, 69 patients received
further treatments. A second-line chemotherapy was admin-
istered to 31.9%, 52.3%, and 27.7% of patients in the GEM,
GEM-T, and GEM-X arms, respectively. The selection of a
second-line chemotherapy was up to the individual investi-
gator, and 5-fluorouracil or platinum-based regimens were
mostly used.
2. Survival and response
One hundred twenty-four patients were assessed for
response. One patient was lost to follow-up right after the
first dose of chemotherapy, and two patients did not
undergo the first follow-up tumor assessment due to their
refusal. Table 2 presents a summary of the response results.
Table 2. Tumor response
Variable GEM (n=47) GEM-T (n=44) GEM-X (n=33)
Objective response rate
Partial response 6 (12.7) 7 (15.9) 7 (21.2)
Stable disease 24 (51) 19 (43.1) 17 (47.2)
Progressive disease 17 (36.1) 18 (40.1) 9 (27.3)
Disease control rate 30 (63.8) 26 (59.1) 24 (72.7)
Treatment duration (wk) 17 10.4 22.8
95% CI 10.6-23.3 7.7-13.0 12.7-32.9
Values are presented as number (%). GEM, gemcitabine; GEM-T, gemcitabine plus erlotinib; GEM-X, gemcitabine plus
capecitabine; CI, confidence interval.
Table 3. Hazard ratio of survival by pretreatment characteristics (GEM-X arm vs. GEM-T arm)
PFS OS
Factor No.
HR 95% CI p-value HR 95% CI p-value
GEM-X:GEM-T 80 0.36 0.20-0.64 0.001a) 0.52 0.28-0.96 0.037a)
Age (yr)
# 65 46 0.36 0.16-0.81 0.013a) 0.33 0.14-0.76 0.01a)
> 65 34 0.24 0.08-0.68 0.007a) 0.94 0.35-2.48 0.903
ECOG performance status
0 or 1 75 0.38 0.21-0.70 0.002a) 0.57 0.30-1.10 0.095
2 5 0.01 0.00-153.5 0.36 0.01 0.00-153.5 0.36
Disease status
Locally advanced 25 0.25 0.07-0.85 0.027a) 0.43 0.13-1.46 0.179
Distant metastatic 43 0.36 0.16-0.77 0.009a) 0.45 0.19-1.07 0.074
CA 19-9 (U/mL)
# 500 40 0.27 0.11-0.62 0.002a) 0.6 0.24-1.52 0.285
> 500 39 0.58 0.26-1.28 0.182 0.45 0.19-1.05 0.067
GEM-X, gemcitabine plus capecitabine; GEM-T, gemcitabine plus erlotinib; PFS, progression-free survival; HR, hazard ratio;
CI, confidence interval; OS, overall survival; ECOG, Eastern Cooperative Oncology Group; CA 19-9, carbohydrate antigen
19-9. a)p < 0.05.
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Fig. 1. Kaplan-Meier curves for PFS (A) and OS (B) of the GEM (red line), GEM-T (green line), and GEM-X arms (blue line).
PFS, progression-free survival; OS, overall survival; GEM, gemcitabine; GEM-T, gemcitabine plus erlotinib; GEM-X, gemc-
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Patients in the GEM-X arm had an improved partial response
rate over GEM and GEM-T (21.2% vs. 12.7% and 15.9%,
respectively) and improved the overall disease control rate
(partial response plus stable disease; 72.7% vs. 63.8% and
59.1%, respectively); however, there was no statistical signif-
icance. The treatment duration was significantly extended in
the GEM-X group. The median duration of gemcitabine treat-
ment was 17, 10.4, and 22.8 weeks in the GEM, GEM-T, and
GEM-X groups, respectively. 
PFS was significantly prolonged in the GEM-X group
compared to the GEM and GEM-T groups (GEM-X vs. GEM;
median, 8.9 vs. 5.2 months; HR, 0.46; 95% CI, 0.27 to 0.79;
p=0.035, and GEM-X vs. GEM-T; median, 8.9 vs. 3.9 months;
HR, 0.36; 95% CI, 0.2 to 0.64; p=0.001). GEM-X significantly
reduced the hazard of progression compared with GEM and
GEM-T (Fig. 1A). The OS was also significantly improved
with GEM-X compared to GEM (median OS, 12.1 vs. 10.4
months; HR, 0.52; 95% CI, 0.28 to 0.94; p=0.033) or to
GEM-T (median OS, 12.1 vs. 9.9 months; HR, 0.52; 95% CI,
0.28 to 0.96; p=0.037) (Fig. 1B). The 1-year survival rates were
44.4% for GEM-X, 25.5% for GEM, and 22.7% for GEM-T.
In the three arms, both partial response and stable disease
extended PFS and OS compared to the progressive disease.
However, there was no significant difference in clinical
benefit between partial response and stable disease (all
p > 0.05 in PFS and OS). 
In the analysis of GEM-X compared to GEM-T, the results
of the subgroup analyses of survival by the baseline charac-
teristic and clinical factor are displayed in Table 3. GEM-X
significantly reduced the hazard of progression compared
with GEM-T in all cases, except high CA 19-9 patients. A
statistically significant benefit of GEM-X in OS was confined
to patients with age less than 65. 
3. Toxicity and dosage modifications
All 127 patients received at least one dose of medication
and were available for an assessment of its toxicity. The
median number of cycles was 4 (range, 1 to 14), 4 (range, 1
to 21), and 7 (range, 1 to 20) cycles in the GEM, GEM-T, and
GEM-X groups, respectively. A total of 239 cycles of GEM,
236 cycles of GEM-T, and 272 cycles of GEM-X were admin-
istered. Adverse events are summarized in Table 4. The treat-
ments were generally well tolerated in all arms. The relative
dose intensity of gemcitabine was 93% for GEM, 98% for
GEM-T, and 94% for GEM-X. The relative dose intensity of
erlotinib was 96% and of capecitabine was 78%. Patients in
the GEM-T arm experienced higher frequencies of rash and
diarrhea, but these were generally grade 1 or 2. The GEM-X
arm was related to more frequent neutropenia and grade 1
or 2 hand-foot syndrome. GEM arm showed more anemia
and thrombocytopenia. Infection was more common in the
GEM arm, and the main cause of infection was biliary
obstruction (80%). Due to older age and ECOG PS 2 patients
having received GEM, it is suggested that anemia, thrombo-
cytopenia, and infection may be related more with poor
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patients’ baseline condition rather than chemotherapeutic
regimen. Of the patients receiving GEM or GEM-T, 27% had
underwent at least one gemcitabine dose reduction. The
main cause of dose modification was hematologic toxicity. A
higher proportion (33%) of patients had a dose reduction in
the GEM-X arm than in other arms. The dose of capecitabine
was reduced in 25% of GEM-X patients (Table 4).
Discussion
We investigated the comparative efficacy of three regi-
mens, GEM, GEM-T, and GEM-X in pancreatic cancer.
GEM-X was superior to GEM and GEM-T, and GEM-T
presented a similar efficacy to GEM. The OS was improved
with GEM-X compared to GEM or to GEM-T. GEM-X also
improved the RR and PFS compared to GEM and GEM-T. In
all groups, metastatic disease, high CA 19-9, and ECOG 2
were related with poor prognosis.
In a comparative analysis of GEM-X and GEM-T, there was
no difference in the extent of disease, age, and ECOG PS of
patients. The improvement in PFS with HR of 0.36 supports
the beneficial effects of capecitabine over erlotinib. The
reduced hazard of progression by capecitabine was consis-
tent across the different subgroups (Table 3). To a lesser
extent, the OS benefit of GEM-X was also consistent across
all subgroups, especially in patients who were less than the
age 65 years, despite age being not a significant prognostic
factor of PFS or OS in the total analysis. A recent retrospec-
tive study supports our results. Compared with GEM-T,
GEM-X exhibited a similar response rate (23.5% vs. 21.1%),
but had a better disease control rate (52.9% vs. 73.7 %) along
with a presentation of longer PFS (2.63 vs. 5.37 months,
p=0.032) and OS (6.23 vs. 14.43 months, p=0.002) [13]. 
The superior efficacy of GEM-X was accompanied by
acceptable levels of toxicity. GEM-X was well tolerated and
not hard to administer compared to GEM or GEM-T. The
relative dose intensity of gemcitabine was not different
between the two groups; 98% for GEM-T and 94% for
GEM-X, and erlotinib was 96% and of capecitabine was 78%.
The dose of capecitabine was reduced for 25% of patients in
the GEM-X arm, mostly owing to grade 3 or 4 neutropenia
without serious events. There was no other frequent grade 3
or 4 adverse event in the GEM-X arm. 
Although erlotinib plus gemcitabine has presented supe-
rior survival over gemcitabine alone in a phase III trial, the
Table 4. Toxicity and dosage modifications
GEM (n=47) GEM-T (n=44) GEM-X (n=36)
Variable
Total G3/4 Total G3/4 Total G3/4
Hematologic toxicity
Anemia 47 (100) 9 (19.1) 44 (100) 7 (15.9) 34 (94.4) 3 (8.3)
Neutropenia 33 (70.2) 15 (31.9) 30 (68.2) 15 (34.1) 30 (83.3) 16 (44.4)
Thrombocytopenia 41 (87.2) 5 (10.6) 28 (63.6) 1 (2.3) 23 (63.8) 2 (5.6)
Non-hematologic toxicity
Diarrhea 9 (19.1) 0 16 (36.4) 0 5 (13.9) 0
Hand-foot syndrome 0 0 0 0 3 (8.3) 0
Skin rash 1 (2.1) 0 11 (25) 0 2 (5.6) 0
Anorexia/nausea 33 (70.2) 0 30 (68.2) 0 27 (75) 0
Vomiting 6 (12.7) 0 6 (13.6) 0 4 (11.2) 0
Infection 16 (34) 11 (23.4) 5 (11.4) 4 (9.1) 5 (13.9) 5 (13.9)
Dose reduction
Gemcitabine 13 (27.6) 12 (27.2) 12 (33.3)
Erlotinib or capecitabine - 0 9 (25)
Treatment discontinuation
Progressive disease 43 (91.5) 38 (86.4) 32 (88.9)
Toxicity 1 (2.1) 1 (2.3) 1 (2.8)
Refuse 3 (6.4) 5 (11.4) 3 (8.3)
Values are presented as number (%). GEM, gemcitabine; GEM-T, gemcitabine plus erlotinib; GEM-X, gemcitabine plus
capecitabine.
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median survival gain was only 0.33 months [3]. GEM-X has
shown clinical benefit in phase II and III trials for pancreatic
cancer [4,5,14]. Our findings indicate that it would be of great
value to further explore the clinical advantage of GEM-X
over other gemcitabine combination regimens for unre-
sectable pancreatic cancer. GEM-T presented a rather disap-
pointing clinical efficacy in our study. This result indicates
that capecitabine may have a more potent antitumor effect
than erlotinib in pancreatic cancer. According to the national
treatment guideline, capecitabine monotherapy is an option
for patients with poor PS or second-line chemotherapy, but
not erlotinib. To select patients who would benefit from
erlotinib, it is mandatory to identify the potential predictive
markers. In non-small cell lung cancer, the diversity of
response to epidermal growth factor receptor (EGFR) tyro-
sine kinase inhibitor has been recognized through several
clinical trials [15,16]. EGFRmutation testing was established
as a mandatory process for using erlotinib as a first-line treat-
ment in non-small cell lung cancer [17,18]. Additionally,
application of potential predictive markers (thymidylate
synthase and thymidine phosphorylase) for capecitabine
might lead to select patients in practice [19,20]. 
Though FOLFIRINOX consisting of oxaliplatin, irinotecan,
fluorouracil, and leucovorin was considered as one of the
first-line regimens for pancreatic cancer [21], gemcitabine
based combination regimens are currently considered as the
standard treatment. It is necessary to find the best combina-
tion for each patient based on predictive biomarker or
patient’s characteristics. Several potential limitations in our
study need to be considered. This study is a non-prospective
and non-randomized investigation with relatively a small
patient population. Our study may provide evidence for
revisiting the clinical benefit of GEM-X regimen, and valida-
tion studies with large and randomized phase III trials are
required.
Conclusion
This study was performed to evaluate the efficacy of
capecitabine in combination with gemcitabine compared
with gemcitabine with or without erlotinib in patients with
locally advanced or metastatic pancreatic cancer. The addi-
tion of capecitabine to gemcitabine presented promising
outcomes over GEM-T in pancreatic cancer. It is worthy to
further investigate which agent has the clinical advantage as
a combination drug with gemcitabine for pancreatic cancer
and to explore predictive markers for each regimen leading
to personalized anti-cancer treatment. 
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